Medical Pharmacology: Chapter 24: Vasoactive Peptide Pharmacology -- Module 4: Vasopressin Pharmacology and Vaptans

Chapter 24: Vasoactive Peptide Pharmacology — Module 4: Vasopressin Pharmacology and Vaptans

1. A 55-year-old woman with a history of hypothyroidism (currently euthyroid on levothyroxine) is admitted with a 3-week history of progressive fatigue, nausea, and mild confusion. Serum sodium is 124 mEq/L. Plasma osmolality is 252 mOsm/kg. Urine osmolality is 490 mOsm/kg. Urine sodium is 52 mEq/L. She is clinically euvolemic. TSH is normal. Adrenal function testing is normal. She has no edema, no ascites, and no evidence of heart failure or cirrhosis. She is awake, tolerating oral intake, and has no urgent neurological symptoms. Fluid restriction has been attempted for 4 days without meaningful sodium improvement. Which of the following is the most appropriate next pharmacological step?

A) Initiate conivaptan intravenous infusion at 20 mg loading dose followed by 20 mg continuous infusion over 24 hours.
B) Initiate tolvaptan 15 mg orally once daily with mandatory serum sodium checks at 6, 12, and 24 hours; do not co-administer fluid restriction; instruct the patient to drink freely in response to thirst.
C) Initiate vasopressin infusion at 0.03 units/minute to activate V2 receptors at low dose and produce a controlled antidiuretic effect that gradually raises serum sodium toward normal.
D) Initiate desmopressin 0.1 mg orally twice daily to provide selective V2 agonism and correct the sodium by promoting regulated water reabsorption.
E) Initiate hypertonic saline (3% NaCl) at 1 mL/kg/hour as first-line therapy given the sodium of 124 mEq/L, which represents moderate hyponatremia requiring urgent correction.

ANSWER: B

Rationale:

This patient has classic SIADH (syndrome of inappropriate antidiuretic hormone secretion): euvolemic hypotonic hyponatremia (plasma osmolality 252 mOsm/kg), inappropriately concentrated urine (urine osmolality 490 mOsm/kg, substantially above plasma osmolality), urine sodium above 40 mEq/L (confirming intact sodium excretion inconsistent with volume depletion), clinical euvolemia, and exclusion of hypothyroidism and adrenal insufficiency. She is alert, tolerating oral intake, and has no urgent neurological symptoms — making this chronic, moderate symptomatic hyponatremia without acute neurological emergency. Fluid restriction has failed after 4 days, which is the standard threshold for escalating to pharmacological therapy. Tolvaptan 15 mg orally once daily is the correct choice: it is an oral selective V2 receptor antagonist approved for euvolemic and hypervolemic hyponatremia in this clinical scenario, and the mandatory protocol requires sodium checks at 6, 12, and 24 hours with freedom to drink in response to thirst — fluid restriction must not be co-administered because the combination risks excessively rapid sodium correction.

Option A: Option A is incorrect: conivaptan is an intravenous-only agent indicated for inpatient use in patients who cannot take oral medications; this patient is tolerating oral intake and there is no indication to use an IV agent when an effective oral alternative exists; additionally, conivaptan's V1a blockade introduces hypotension risk unnecessarily.
Option C: Option C is incorrect: vasopressin is a V1a and V2 agonist — not an antagonist — and administering it would worsen hyponatremia by promoting further water retention; it has no role in SIADH management.
Option D: Option D is incorrect: desmopressin is a selective V2 agonist (not antagonist) that produces antidiuresis; administering it to a patient with SIADH who already has excess AVP-mediated water retention would compound the hyponatremia, not correct it.
Option E: Option E is incorrect: hypertonic saline is indicated for acute symptomatic hyponatremia with active neurological compromise (seizure, obtundation, herniation); this patient has mild confusion consistent with chronic moderate hyponatremia but no acute neurological emergency requiring hypertonic saline, and initiating hypertonic saline when an oral vaptan is available and appropriate would be an unnecessary escalation.

2. A 67-year-old man undergoes elective right hemicolectomy for colon cancer. On postoperative day 3 he is noted to have serum sodium of 121 mEq/L. Plasma osmolality is 249 mOsm/kg. Urine osmolality is 530 mOsm/kg. Urine sodium is 61 mEq/L. He is euvolemic, hemodynamically stable, and mildly confused. He has a nasogastric tube in place on low intermittent suction and is receiving nothing by mouth pending return of bowel function. The surgical team asks for a nephrology recommendation on vaptan therapy. Which of the following most appropriately guides agent selection in this patient?

A) Tolvaptan 15 mg crushed and administered via nasogastric tube is the preferred option because it has superior V2 selectivity over all intravenous alternatives and avoids the hemodynamic risks of non-selective agents.
B) No vaptan is appropriate in the postoperative setting; the hyponatremia should be managed with isotonic saline infusion to restore the sodium to 130 mEq/L before any vaptan is considered.
C) Satavaptan oral suspension should be initiated because it is the only vaptan formulation approved for inpatient administration in patients with postoperative euvolemic hyponatremia.
D) Conivaptan intravenous infusion is the appropriate agent: it is the only FDA-approved intravenous vaptan, permitting use in a patient who cannot receive oral medications; it is administered as a 20 mg IV loading dose over 30 minutes followed by 20 mg continuous infusion over 24 hours, with a maximum duration of 4 days.
E) Desmopressin intravenous infusion is the appropriate vaptan in this patient because it selectively activates V2 receptors without vasopressor effect, producing aquaresis while avoiding the hemodynamic risks of V1a-active agents.

ANSWER: D

Rationale:

When a patient with euvolemic hyponatremia consistent with SIADH cannot take oral medications, conivaptan (Vaprisol) is the only FDA-approved intravenous vaptan and is therefore the correct pharmacological choice. Its approved dosing regimen is a 20 mg IV loading dose administered over 30 minutes followed by a continuous infusion of 20 mg over 24 hours, with the option to increase to 40 mg per 24 hours if the sodium response is inadequate, for a maximum treatment duration of 4 days. The 4-day limit reflects its inpatient-only indication and the monitoring requirements imposed by its dual V1a/V2 blockade, which can cause hypotension through V1a-mediated loss of vasomotor tone.

Option A: Option A is incorrect: while off-label nasogastric administration of crushed tolvaptan is occasionally practiced, it is not the approved or purpose-designed approach for a patient who cannot take oral medications; the approved intravenous option (conivaptan) provides reliable bioavailability without the uncertainty of gastrointestinal absorption in a postoperative patient with an NG tube on suction.
Option B: Option B is incorrect: isotonic saline is the treatment of hypovolemic hyponatremia, where the goal is to restore intravascular volume and remove the hemodynamic AVP stimulus; this patient is euvolemic with a urine sodium of 61 mEq/L, confirming SIADH physiology rather than volume depletion — isotonic saline would not correct the hyponatremia and could worsen it by providing more free water relative to sodium.
Option C: Option C is incorrect: satavaptan is not FDA-approved; it failed to receive approval after Phase III trials in cirrhosis showed no benefit and raised survival concerns, and it has no current clinical role anywhere in the world.
Option E: Option E is incorrect: desmopressin is a V2 agonist, not a vaptan or V2 antagonist; administering it to a patient with SIADH would intensify antidiuresis and worsen hyponatremia rather than producing aquaresis.

3. A 62-year-old woman with SIADH secondary to small cell lung carcinoma is started on tolvaptan 15 mg orally for a serum sodium of 122 mEq/L. Eight hours after the first dose, her serum sodium is 130 mEq/L — a rise of 8 mEq/L. She reports no thirst and has consumed only 150 mL of fluid since the dose was given. The nurse notifies the team. Which of the following is the most appropriate immediate management?

A) Withhold the next tolvaptan dose and offer oral free water immediately; if the patient cannot drink adequately or sodium continues to rise, administer 5% dextrose in water (D5W) intravenously to slow the rate of correction and prevent osmotic demyelination syndrome.
B) Continue tolvaptan at the same dose and recheck sodium in 12 hours; a rise of 8 mEq/L in 8 hours is within acceptable limits and does not require any intervention.
C) Double the tolvaptan dose to 30 mg to accelerate sodium correction to target while the patient is still in the monitored setting, then taper once sodium exceeds 130 mEq/L.
D) Administer 3% hypertonic saline at 0.5 mL/kg/hour to counteract the aquaretic effect of tolvaptan and stabilize the rate of sodium rise at a controlled level.
E) Discontinue tolvaptan permanently and initiate fluid restriction to 500 mL per day as the only safe management strategy once a vaptan has produced an excessively rapid sodium rise.

ANSWER: A

Rationale:

A rise of 8 mEq/L in 8 hours is a significant early warning signal: if this rate is maintained over 24 hours, the total rise would reach approximately 24 mEq/L — far exceeding the safe ceiling of 10 to 12 mEq/L per 24 hours established by the 2013 Verbalis consensus panel. The prescribed management when sodium rises more than 8 mEq/L in the first 8 hours of vaptan therapy is to withhold the vaptan and offer the patient oral free water immediately to buffer the ongoing aquaresis-driven sodium rise; if the patient cannot drink adequately — as this patient demonstrates by having consumed only 150 mL despite active aquaresis — D5W administered intravenously provides the hypotonic free water needed to slow the rate of sodium correction and reduce osmotic demyelination syndrome (ODS) risk. The absent thirst sensation in this patient is itself a critical finding, as inability to perceive and respond to thirst is an absolute contraindication to vaptan initiation that should have been assessed before the first dose was given.

Option B: Option B is incorrect: a rise of 8 mEq/L in only 8 hours is not within acceptable limits for ongoing therapy — extrapolating this rate to 24 hours produces a total rise of approximately 24 mEq/L, which is double the safe ceiling; no action is not an acceptable response.
Option C: Option C is incorrect: doubling the dose when the sodium is already rising at a dangerous rate would accelerate aquaresis and compound the risk of overcorrection; tolvaptan dose escalation is appropriate only when the sodium response at 24 hours is inadequate, not when it is excessive.
Option D: Option D is incorrect: hypertonic saline would further raise serum sodium rather than slow the rise; it is contraindicated in this scenario and would directly worsen the overcorrection being addressed.
Option E: Option E is incorrect: while tolvaptan should be withheld at this time, permanent discontinuation is not necessarily indicated for all patients in whom sodium rises faster than expected on the first dose — the appropriate response is to withhold, provide free water, reassess the clinical picture, and address whether intact thirst sensation was present before any future redosing; fluid restriction to 500 mL per day is contraindicated in combination with vaptan therapy precisely because it removes the patient's ability to buffer aquaresis.

4. A 71-year-old man with ischemic cardiomyopathy (ejection fraction 25%) is admitted for acute decompensated heart failure. He has 3+ bilateral pitting edema, crackles to the lung bases, and a weight gain of 7 kg over 10 days. Serum sodium is 126 mEq/L. He is started on furosemide infusion, but after 48 hours his sodium has risen only to 128 mEq/L despite adequate diuresis. The cardiology attending proposes adding tolvaptan and cites clinical trial evidence. Which of the following most accurately characterizes the evidence base and appropriate clinical role of tolvaptan in this patient?

A) Tolvaptan is contraindicated in hypervolemic hyponatremia associated with heart failure because V2 blockade eliminates the compensatory water-retention mechanism that maintains cardiac preload in low-output states.
B) The EVEREST trial demonstrated that tolvaptan reduces all-cause mortality and cardiovascular hospitalization in acute decompensated heart failure, establishing it as a guideline-recommended agent for long-term use in heart failure with hyponatremia.
C) Tolvaptan is appropriate for short-term inpatient correction of this patient's symptomatic hypervolemic hyponatremia; the EVEREST trial demonstrated significant improvement in dyspnea and body weight during the first week of hospitalization but no reduction in all-cause mortality or the composite cardiovascular endpoint, restricting tolvaptan's role to acute symptom management rather than as a mortality-reducing therapy.
D) Tolvaptan should be withheld until the sodium falls below 120 mEq/L, as the EVEREST trial demonstrated benefit only in patients with severe hyponatremia below this threshold.
E) Tolvaptan is indicated only for euvolemic hyponatremia; the FDA has not approved it for hypervolemic hyponatremia associated with heart failure because the aquaresis produced by V2 blockade cannot overcome the ongoing neurohormonal free-water retention in low cardiac output states.

ANSWER: C

Rationale:

Tolvaptan is approved by the FDA for both euvolemic and hypervolemic hyponatremia, and the EVEREST trial (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) provides the key evidence base for its use in the heart failure context. EVEREST randomized 4,133 patients hospitalized for acute decompensated heart failure to tolvaptan 30 mg daily or placebo for a median of 9.9 months. Tolvaptan significantly improved dyspnea and reduced body weight during the first week of hospitalization — demonstrating clinically meaningful short-term benefit. However, the primary dual endpoint of all-cause mortality and cardiovascular death or hospitalization was not met, with no difference between groups over the full follow-up period. Current ACC/AHA/HFSA heart failure guidelines therefore do not recommend tolvaptan as a mortality-reducing agent; its clinical role is restricted to short-term inpatient correction of symptomatic or severe hypervolemic hyponatremia — precisely the situation this patient presents. Tolvaptan should be initiated in the monitored inpatient setting with sodium checks at 6, 12, and 24 hours and without concurrent fluid restriction.

Option A: Option A is incorrect: tolvaptan is not contraindicated in hypervolemic hyponatremia from heart failure; V2 blockade reduces free-water retention without eliminating the neurohormonal mechanisms that maintain cardiac preload, and the EVEREST trial specifically studied this population without identifying a worsened hemodynamic safety signal at the approved doses.
Option B: Option B is incorrect: EVEREST did not demonstrate mortality or hospitalization benefit — the primary endpoint was not met; tolvaptan is not a guideline-recommended long-term agent in heart failure.
Option D: Option D is incorrect: the SALT-1/SALT-2 trials and EVEREST enrolled patients with sodium below 135 mEq/L; there is no evidence- or guideline-based threshold of 120 mEq/L below which tolvaptan is restricted, and this patient's sodium of 126 mEq/L is within the approved indication.
Option E: Option E is incorrect: tolvaptan is FDA-approved for both euvolemic and hypervolemic hyponatremia, and the Samsca prescribing information explicitly includes hypervolemic hyponatremia in heart failure as an approved indication.

5. A 58-year-old woman with SIADH from pulmonary sarcoidosis is started on tolvaptan 15 mg daily. The admitting intern writes the following orders: tolvaptan 15 mg orally once daily, strict fluid restriction to 800 mL per day, sodium checks every 24 hours. The attending physician reviews the orders and immediately identifies a prescribing error. Which element of the order set represents the most dangerous management error and why?

A) The tolvaptan starting dose of 15 mg is too low for SIADH secondary to a granulomatous disease; the correct starting dose in this etiology is 30 mg daily due to higher baseline AVP drive from inflammatory cytokines.
B) Serum sodium monitoring at every 24 hours is insufficient; the only error is the monitoring interval, which should be every 6, 12, and 24 hours after the first dose.
C) The concurrent prescription of an underlying disease treatment (sarcoidosis) is missing; tolvaptan cannot be used until the underlying cause of SIADH is being actively addressed with corticosteroids.
D) Tolvaptan is contraindicated in SIADH from pulmonary disease because aquaresis in the setting of pulmonary venous hypertension may worsen ventilation-perfusion mismatch.
E) Co-administering strict fluid restriction with tolvaptan is the critical error: tolvaptan produces aquaresis that the patient can buffer only by drinking freely in response to thirst; restricting fluid intake to 800 mL per day removes that buffer, creating a risk of excessively rapid and uncontrolled sodium correction that may exceed the safe ceiling of 10 to 12 mEq/L per 24 hours and precipitate osmotic demyelination syndrome.

ANSWER: E

Rationale:

Fluid restriction and vaptan therapy must never be co-administered, and this is explicitly stated in the tolvaptan prescribing information and reinforced by the 2013 Verbalis expert panel. The reason is mechanistic: tolvaptan blocks V2 receptors on collecting duct principal cells, preventing AQP2 (aquaporin-2) insertion and producing ongoing free-water excretion (aquaresis) regardless of the patient's fluid intake. The only physiological mechanism available to buffer this aquaresis-driven sodium rise is the patient drinking freely in response to thirst — oral free water ingestion replaces the excreted water and moderates the rate of sodium increase. If fluid intake is simultaneously restricted to 800 mL per day while aquaresis continues, the patient cannot complete this buffer loop: sodium rises at the unrestricted aquaretic rate with no oral replacement, and the combined effect of active V2 blockade plus fluid deprivation can produce a sodium rise that far exceeds 12 mEq/L per 24 hours, placing the patient at high risk of osmotic demyelination syndrome. The monitoring interval error (option B) is a real concern but is less immediately dangerous than the co-prescription that actively drives sodium overcorrection.

Option A: Option A is incorrect: 15 mg once daily is the correct and approved starting dose for tolvaptan in all forms of euvolemic and hypervolemic hyponatremia regardless of the underlying SIADH etiology; there is no dose adjustment by disease cause in the prescribing information.
Option B: Option B is incorrect: the monitoring interval is indeed an error (every 6, 12, and 24 hours is required), but it is a secondary concern compared with the fluid restriction co-prescription, which actively creates the conditions for dangerous overcorrection rather than merely delaying detection of it.
Option C: Option C is incorrect: tolvaptan can and should be initiated for urgent sodium correction while underlying SIADH causes are investigated and treated concurrently; there is no requirement to wait for disease-specific therapy to be underway before starting vaptan.
Option D: Option D is incorrect: tolvaptan has no pharmacological mechanism that would worsen ventilation-perfusion mismatch; aquaresis reduces total body free-water content and raises serum sodium — it does not affect pulmonary hemodynamics in a clinically meaningful way at approved doses.

6. A 34-year-old man with central diabetes insipidus (central DI) following resection of a pituitary macroadenoma is being transitioned from inpatient subcutaneous desmopressin to an outpatient oral regimen. He reports frequent upper respiratory infections and seasonal allergic rhinitis causing nasal congestion for 3 to 4 months of the year. His endocrinologist is choosing between intranasal and oral desmopressin for long-term outpatient management. Which of the following most accurately reflects the pharmacological rationale for the route selection in this patient?

A) Intranasal desmopressin is always preferred over oral for central DI because its bioavailability of approximately 40% is substantially higher than oral desmopressin's bioavailability of less than 1%, making dose titration more precise and predictable in all patients.
B) Oral desmopressin is the preferred formulation for this patient's long-term outpatient management: although its bioavailability is approximately 5% relative to the nasal route, absorption is more consistent and predictable than intranasal desmopressin in a patient with recurrent nasal congestion and mucosal disease, which impair intranasal absorption and lead to erratic antidiuretic responses.
C) Subcutaneous desmopressin should be continued as the outpatient formulation because oral and intranasal routes have equivalent efficacy, and subcutaneous administration avoids all mucosal absorption variability.
D) Intranasal desmopressin must be used exclusively for central DI because the oral formulation was voluntarily withdrawn from the diabetes insipidus indication in the United States due to concerns about unpredictable absorption causing hypernatremia in outpatient settings.
E) Route selection is not clinically meaningful for desmopressin in central DI because the drug's long plasma half-life of 18 to 24 hours provides sustained V2 receptor occupancy regardless of the absorption rate; once or twice weekly dosing by any route achieves adequate antidiuresis.

ANSWER: B

Rationale:

Desmopressin is available in three formulations for central DI: intranasal spray (10 to 40 mcg once or twice daily), oral tablet (0.1 to 0.4 mg two to three times daily), and subcutaneous injection (1 to 4 mcg once or twice daily). The intranasal route offers rapid onset but is critically dependent on intact nasal mucosal absorption — nasal congestion, rhinitis, mucosal edema, or any condition that alters the nasal epithelium impairs absorption and produces erratic and unpredictable antidiuretic responses. In this patient, recurrent allergic rhinitis with nasal congestion for 3 to 4 months per year would substantially destabilize sodium control during those periods if the intranasal route were relied upon. While the oral formulation has a lower absolute bioavailability of approximately 5% relative to intranasal dosing, its absorption from the gastrointestinal mucosa is far more consistent and predictable in patients with upper respiratory or nasal mucosal disease, making it the preferred long-term formulation for stable outpatient management in this clinical context.

Option A: Option A is incorrect: intranasal desmopressin's bioavailability is not 40%; its apparent bioavailability relative to subcutaneous injection is substantially lower, and the comparison stated is inaccurate; more importantly, bioavailability advantage is meaningless when absorption is rendered inconsistent by mucosal disease.
Option C: Option C is incorrect: subcutaneous injection is effective and appropriate for acute inpatient management but is not the standard long-term outpatient formulation for central DI when oral or intranasal options provide adequate control; continued subcutaneous administration in a stable outpatient without a specific indication for parenteral therapy is not the standard of care.
Option D: Option D is incorrect: the oral desmopressin formulation for central DI has not been withdrawn in the United States; the formulation that was voluntarily withdrawn was the intranasal spray for the pediatric nocturnal enuresis indication — not the diabetes insipidus indication — due to hyponatremia-associated seizures in children who drank excessively before bedtime.
Option E: Option E is incorrect: desmopressin's plasma half-life after therapeutic dosing is several hours (not 18 to 24 hours), and once or twice weekly dosing would produce intervals of polyuria and hypernatremia between doses; standard dosing for central DI is once or twice daily, not weekly.

7. A 27-year-old woman with a known bleeding disorder presents for pre-operative evaluation before elective knee arthroscopy. Her hematologist's records confirm a diagnosis of type 2B von Willebrand disease (type 2B vWD), characterized by a gain-of-function mutation in vWF that produces abnormal vWF with spontaneously increased affinity for platelet GPIb receptors. Her baseline platelet count is 98,000/mcL (mildly reduced from her usual baseline of 110,000/mcL). A surgical colleague suggests administering desmopressin preoperatively to raise vWF and factor VIII levels. Which of the following most accurately identifies whether desmopressin is appropriate and why?

A) Desmopressin is appropriate and will be effective because the structural abnormality in type 2B vWD affects only the collagen-binding domain of vWF, leaving the Weibel-Palade body storage and release mechanism intact; the released vWF will adequately support platelet adhesion at the site of vascular injury.
B) Desmopressin is appropriate at a reduced dose of 0.15 mcg/kg (half the standard hemostatic dose) because the lower amount of released vWF will be insufficient to trigger the spontaneous platelet aggregation seen at full doses.
C) Desmopressin is appropriate because type 2B vWD patients lack functional Weibel-Palade bodies and therefore cannot release vWF in response to desmopressin; the drug has no effect and causes no harm in this subtype.
D) Desmopressin is contraindicated in type 2B vWD: administration triggers rapid exocytic release of structurally abnormal high-molecular-weight vWF multimers from Weibel-Palade bodies; these multimers bind platelet GPIb constitutively and cause acute platelet aggregation and thrombocytopenia, paradoxically worsening hemostasis rather than improving it; vWF concentrate is required for perioperative hemostatic coverage in this patient.
E) Desmopressin is appropriate because the mildly reduced baseline platelet count confirms that spontaneous vWF-platelet aggregation is already occurring at a low level; desmopressin will saturate the remaining GPIb receptor sites and paradoxically prevent further spontaneous aggregation during the perioperative period.

ANSWER: D

Rationale:

Type 2B von Willebrand disease is caused by a gain-of-function mutation in the vWF gene that produces vWF with spontaneously increased affinity for platelet glycoprotein Ib (GPIb). Even under resting conditions, this abnormal vWF binds platelet GPIb without requiring the uncoiling shear forces that normally trigger vWF-platelet interaction, resulting in continuous low-grade platelet aggregation and mild chronic thrombocytopenia — consistent with this patient's baseline platelet count of approximately 110,000/mcL. When desmopressin is administered, it activates V2 receptors on vascular endothelial cells and triggers rapid exocytic release of vWF multimers — including the high-molecular-weight forms — from Weibel-Palade bodies. In type 2B vWD, the released multimers are structurally abnormal and bind platelet GPIb constitutively upon entering the circulation, triggering acute and potentially severe platelet aggregation and thrombocytopenia. This paradoxical worsening of hemostasis is the pharmacological basis for the absolute contraindication: administering desmopressin to a type 2B patient is the pharmacological equivalent of delivering a bolus of proaggregant vWF directly into the circulation. Perioperative hemostatic management of type 2B vWD requires vWF concentrate, which provides structurally normal exogenous vWF without the GPIb hyperbinding defect.

Option A: Option A is incorrect: the structural defect in type 2B vWD is in the GPIb-binding domain of vWF (not the collagen-binding domain), and the released vWF has pathologically increased rather than normal platelet-binding affinity.
Option B: Option B is incorrect: there is no dose of desmopressin that selectively releases insufficient vWF to trigger aggregation in type 2B vWD — the contraindication is absolute, not dose-dependent; any release of abnormal multimers from Weibel-Palade bodies can precipitate platelet aggregation.
Option C: Option C is incorrect: type 2B vWD patients have intact Weibel-Palade bodies and a releasable vWF pool — the stored vWF is structurally abnormal but present; desmopressin does have an effect and that effect is harmful.
Option E: Option E is incorrect: receptor saturation by excess vWF does not prevent further platelet aggregation in type 2B vWD; the increased affinity is intrinsic to the mutant vWF molecule and cannot be pharmacologically blocked by additional vWF binding.

8. A 44-year-old man presents to the emergency department with a 6-day history of profuse watery diarrhea, poor oral intake, and progressive weakness. On examination he has a heart rate of 112 bpm, blood pressure 94/60 mmHg supine that drops to 76/44 mmHg standing, dry mucous membranes, and reduced skin turgor. Serum sodium is 119 mEq/L. Plasma osmolality is 247 mOsm/kg. Urine osmolality is 710 mOsm/kg. Urine sodium is 7 mEq/L. The emergency physician considers initiating tolvaptan for the hyponatremia. Which of the following most accurately identifies the error in this clinical reasoning and the correct management?

A) The urine sodium of 7 mEq/L indicates maximal renal sodium conservation — the appropriate physiological response to intravascular volume depletion — confirming hypovolemic hyponatremia; tolvaptan is absolutely contraindicated because aquaresis in a volume-depleted patient would worsen hemodynamic compromise; the correct treatment is isotonic saline to restore intravascular volume, which will remove the hemodynamic AVP stimulus and allow the kidney to spontaneously correct the hyponatremia.
B) The urine sodium of 7 mEq/L is the hallmark of SIADH in a patient with concurrent volume depletion; both tolvaptan and isotonic saline should be administered simultaneously to address both the free-water excess and the volume deficit.
C) The urine sodium of 7 mEq/L indicates that AVP secretion is autonomous rather than hemodynamically driven; tolvaptan should be initiated at 15 mg daily alongside intravenous saline to correct both the underlying sodium physiology and the volume deficit simultaneously.
D) Tolvaptan is appropriate in this patient because the hyponatremia is profound (119 mEq/L) and the clinical urgency overrides the standard volume-status assessment; once the sodium reaches 125 mEq/L on tolvaptan, the agent can be switched to isotonic saline.
E) The finding of concentrated urine (urine osmolality 710 mOsm/kg) confirms SIADH because appropriate dilution of urine would be expected in a volume-depleted patient; tolvaptan is therefore indicated as first-line therapy before isotonic saline is attempted.

ANSWER: A

Rationale:

The urine sodium of 7 mEq/L is the single most diagnostically decisive laboratory value in this case. In SIADH, the kidney continues to excrete sodium in the face of hyponatremia because volume receptors do not perceive a deficit — hence the SIADH diagnostic criterion of urine sodium above 40 mEq/L on a normal sodium intake. In contrast, when hyponatremia results from true volume depletion (as in this patient with 6 days of diarrhea, orthostatic hypotension, tachycardia, and clinical dehydration), the kidney is simultaneously maximizing sodium reabsorption through aldosterone and sympathetic activation — producing urine sodium below 20 mEq/L, and in this case as low as 7 mEq/L — while AVP is released non-osmotically via baroreceptor activation to retain water and defend blood pressure. This is the appropriate physiological response to volume loss, not inappropriate AVP secretion. Tolvaptan is absolutely contraindicated in hypovolemic hyponatremia: producing aquaresis — electrolyte-free water loss — in a patient who is already volume-depleted and hemodynamically compromised would further reduce intravascular volume, worsen orthostatic hypotension, and potentially precipitate acute kidney injury. The correct treatment is isotonic saline to restore intravascular volume; as volume is replaced, the baroreceptor AVP stimulus resolves, AVP levels fall, and the kidney spontaneously begins to dilute urine and correct the sodium — a process that must itself be monitored carefully to avoid overcorrection and ODS.

Option B: Option B is incorrect: the urine sodium of 7 mEq/L does not indicate SIADH; it confirms volume-depleted physiology; the two conditions have opposite urine sodium findings and opposite initial treatments.
Option C: Option C is incorrect: urine sodium of 7 mEq/L indicates hemodynamically driven AVP secretion, not autonomous secretion — the kidney's behavior is appropriate, not inappropriate; tolvaptan is not indicated.
Option D: Option D is incorrect: the depth of hyponatremia does not override the volume-status assessment; a vaptan in a volume-depleted patient is directly harmful regardless of how low the sodium is; tolvaptan is not titrated on top of saline in hypovolemia.
Option E: Option E is incorrect: concentrated urine in volume depletion is the expected and appropriate renal response — AVP is released via baroreceptors to defend blood pressure, and the kidney appropriately concentrates urine; this is not SIADH, and concentrated urine alone does not confirm SIADH without euvolemia and urine sodium above 40 mEq/L.

9. A 19-year-old man with mild hemophilia A (baseline factor VIII 22% of normal) undergoes a dental extraction on a Monday. His hematologist prescribes desmopressin 0.3 mcg/kg IV before the procedure and again on Tuesday and Wednesday to cover the healing period. On Monday his factor VIII rises from 22% to 74% of normal — an adequate hemostatic response. On Tuesday his factor VIII rises from 22% to 51%. On Wednesday his factor VIII rises only to 29% despite the same dose. Which of the following most accurately explains the progressively diminishing factor VIII response?

A) V2 receptor downregulation: repeated desmopressin administration causes internalization and degradation of endothelial V2 receptors, reducing the cAMP response to each successive dose below the threshold required for Weibel-Palade body exocytosis.
B) Accelerated factor VIII clearance: repeated desmopressin doses upregulate the von Willebrand factor-cleaving protease ADAMTS13, which progressively degrades the released factor VIII-vWF complexes more rapidly with each successive administration.
C) Weibel-Palade body depletion: each desmopressin dose triggers exocytic release of the stored vWF and factor VIII pool from endothelial Weibel-Palade bodies; the granule contents require 24 to 48 hours to fully replenish, and with daily dosing the available releasable pool is progressively exhausted, reducing the amplitude of each successive response even though V2 receptor signaling and cAMP generation remain intact.
D) Pharmacokinetic tachyphylaxis: the desmopressin molecule undergoes accelerated hepatic CYP3A4 induction with repeated exposure, progressively shortening its plasma half-life and reducing the duration of V2 receptor occupancy achieved after each dose.
E) Osmotic feedback inhibition: the rising factor VIII and vWF levels after the first two doses activate a negative feedback loop through osmoreceptors in the hypothalamus, suppressing subsequent AVP-receptor-mediated endothelial exocytosis by reducing hypothalamic parvocellular neuron firing.

ANSWER: C

Rationale:

The progressive diminution in factor VIII response on days 2 and 3 is the clinical manifestation of tachyphylaxis through Weibel-Palade body depletion — a pharmacodynamic storage biology phenomenon. Weibel-Palade bodies are elongated endothelial storage organelles that serve as the only significant vascular pool for vWF multimers and factor VIII. A single desmopressin dose produces rapid, cAMP/PKA-mediated exocytosis of this preformed pool, achieving the two- to fivefold factor VIII rise seen on Monday. Restoring the granule pool to pre-dose levels requires approximately 24 to 48 hours of endothelial biosynthesis and trafficking. With daily dosing the pool is being depleted faster than it can replenish: the Tuesday dose activates V2 receptors and generates cAMP normally (signaling is intact) but finds a partially depleted pool, producing a smaller rise; the Wednesday dose finds the pool substantially exhausted, yielding a rise barely above baseline. This is the pharmacological basis for desmopressin being suitable only for short-duration hemostatic coverage of 2 to 3 days; procedures requiring sustained perioperative hemostasis across more than 2 to 3 days require vWF/factor VIII concentrate.

Option A: Option A is incorrect: V2 receptor downregulation is not the established mechanism of desmopressin tachyphylaxis; the endothelial V2 receptor remains functionally responsive across standard clinical dosing intervals, and the progressive loss of response is due to granule depletion rather than receptor loss.
Option B: Option B is incorrect: desmopressin does not upregulate ADAMTS13; ADAMTS13 activity is not altered by repeated desmopressin dosing, and protease-mediated degradation is not the mechanism of tachyphylaxis.
Option D: Option D is incorrect: desmopressin is not metabolized by CYP3A4 and does not induce CYP3A4; tachyphylaxis is a pharmacodynamic phenomenon, not a pharmacokinetic one, and the drug's plasma half-life does not shorten with repeated administration.
Option E: Option E is incorrect: there is no osmoreceptor-mediated negative feedback loop that suppresses endothelial desmopressin responses; osmoreceptors regulate hypothalamic AVP secretion, not endothelial V2 receptor signaling or Weibel-Palade body exocytosis.

10. A 41-year-old man with autosomal dominant polycystic kidney disease (ADPKD) and an eGFR (estimated glomerular filtration rate) of 52 mL/min/1.73m² is being considered for tolvaptan (Jynarque) to slow kidney cyst growth. His baseline liver enzymes are normal. The nephrologist reviews the FDA prescribing information before initiating therapy. Which of the following most accurately describes the hepatotoxicity risk and the mandatory monitoring and program requirements associated with tolvaptan at the ADPKD indication dose?

A) The hepatotoxicity risk applies only to patients with pre-existing liver disease or alcohol use; patients with normal baseline liver enzymes and no hepatic risk factors can receive Jynarque without any additional monitoring beyond standard annual labs.
B) Tolvaptan at the ADPKD dose carries a hepatotoxicity risk identical to that of the hyponatremia dose (Samsca); both formulations carry the same black box warning and the same monitoring requirements because the hepatotoxicity mechanism is a class effect of V2 receptor antagonism at any dose.
C) The hepatotoxicity risk associated with Jynarque was identified only in post-marketing surveillance; no signal was detected during clinical trials, and the FDA black box warning was added retrospectively based on spontaneous adverse event reports rather than prospective trial data.
D) Jynarque requires baseline liver enzyme measurement only; if baseline values are normal, no further monitoring is required because hepatotoxicity from tolvaptan is an idiosyncratic reaction that cannot be predicted or detected by serial liver enzyme monitoring.
E) Jynarque carries an FDA black box warning for serious and potentially fatal liver injury at the higher doses used in the ADPKD indication (up to 90 to 120 mg daily in split doses); a REMS (Risk Evaluation and Mitigation Strategy) program is required, with monthly liver enzyme monitoring for the first 18 months and every 3 months thereafter; the drug must be discontinued promptly if ALT or AST rise to specified threshold levels, and this monitoring obligation applies to all patients regardless of baseline liver function.

ANSWER: E

Rationale:

At the doses used in the ADPKD indication — substantially higher than those for hyponatremia, reaching up to 45 mg in the morning and 15 mg in the afternoon (titrating upward to 60 mg morning/30 mg afternoon) — tolvaptan carries an FDA black box warning for serious, potentially fatal liver injury. In ADPKD clinical trials, liver transaminase elevations occurred more frequently in tolvaptan-treated patients than in placebo recipients, and three cases of irreversible liver failure were reported — a prospective trial signal, not a post-marketing finding. The FDA required implementation of a REMS (Risk Evaluation and Mitigation Strategy) program as a condition of approval, which mandates monthly liver enzyme monitoring for the first 18 months of therapy and every 3 months thereafter. If ALT or AST rises to specified threshold levels (typically above 2 to 3 times the upper limit of normal with symptoms, or above 8 times the upper limit of normal regardless of symptoms), the drug must be promptly discontinued. This monitoring obligation applies to all patients initiating Jynarque regardless of baseline liver function, because normal baseline values do not predict which patients will develop drug-induced liver injury during therapy. This hepatotoxicity warning and the associated REMS requirements are specific to the ADPKD indication at its higher doses and do not apply to the hyponatremia indication (Samsca, 15 to 60 mg) approved only for short-term inpatient use.

Option A: Option A is incorrect: the REMS monitoring requirement applies to all patients receiving Jynarque regardless of baseline liver disease history or absence of hepatic risk factors; normal baseline enzymes do not waive the obligation.
Option B: Option B is incorrect: the black box warning and REMS requirements are specific to the ADPKD indication and its higher doses; the hyponatremia formulation (Samsca) does not carry the same REMS obligation, and liver injury at Samsca doses has not been established as a class effect.
Option C: Option C is incorrect: the hepatotoxicity signal emerged from prospective clinical trial data in the ADPKD development program — not post-marketing surveillance — and the three cases of liver failure were identified in the trial population before regulatory approval.
Option D: Option D is incorrect: serial liver enzyme monitoring is the central safety requirement of the REMS program precisely because early detection of rising transaminases allows drug discontinuation before irreversible liver failure develops; dismissing serial monitoring as uninformative contradicts the prescribing information and the regulatory basis for approval.

11. A 53-year-old woman with alcoholic liver disease and cirrhosis presents with confusion and a serum sodium of 116 mEq/L. Her family reports the confusion has been worsening gradually over the past 2 weeks. Urine osmolality is 460 mOsm/kg. Urine sodium is 48 mEq/L. She is euvolemic. The admitting team determines this is chronic euvolemic hyponatremia consistent with SIADH physiology and initiates treatment. Fourteen hours after initiation of therapy, her serum sodium is 129 mEq/L — a rise of 13 mEq/L. She remains neurologically stable. Which of the following most accurately characterizes the safety concern and the correct management response?

A) A rise of 13 mEq/L in 14 hours is within acceptable limits for chronic hyponatremia; the established safe correction ceiling of 20 mEq/L per 24 hours has not been exceeded, and no corrective action is required.
B) A rise of 13 mEq/L in 14 hours is dangerous: the established safe ceiling for chronic hyponatremia is 10 to 12 mEq/L per 24 hours, and this rate — if maintained — would substantially exceed that limit; treatment should be paused and the patient offered oral free water or D5W intravenously to slow the rate of rise and reduce the risk of osmotic demyelination syndrome, which characteristically presents 2 to 6 days after overcorrection with dysarthria, dysphagia, and quadriparesis.
C) The rise of 13 mEq/L in 14 hours is dangerous only if the sodium exceeds 135 mEq/L within 24 hours; if the final 24-hour rise remains below 135 mEq/L, no ODS risk exists regardless of the rate of change from the starting sodium.
D) The 13 mEq/L rise in 14 hours is appropriate because this patient started at a sodium of 116 mEq/L; the safe correction ceiling of 10 to 12 mEq/L per 24 hours applies only to patients with starting sodium above 125 mEq/L, where the risk of ODS is higher due to the greater magnitude of brain adaptation.
E) The 13 mEq/L rise indicates the SIADH has self-resolved; no corrective action is needed and the treating agent should be discontinued permanently given the spontaneous sodium normalization trend.

ANSWER: B

Rationale:

The 2013 Verbalis expert panel consensus establishes the safe correction target for chronic hyponatremia as 4 to 8 mEq/L per 24 hours, with an absolute ceiling of 10 to 12 mEq/L per 24 hours and no more than 18 mEq/L per 48 hours. A rise of 13 mEq/L in 14 hours is significantly above the safe rate: extrapolating this rate to 24 hours projects a total rise of approximately 22 mEq/L, nearly double the absolute ceiling. In a patient with chronic hyponatremia — where brain cells have adapted to the hypo-osmolar environment by exporting organic osmoles over days to weeks — rapid correction creates an osmotic gradient that draws water out of brain cells, producing demyelination of the pons and other susceptible structures. ODS symptoms (dysarthria, dysphagia, quadriparesis, and potentially locked-in state in severe cases) characteristically emerge 2 to 6 days after the overcorrection event, not immediately — meaning the patient may appear neurologically stable at the time of overcorrection while the demyelinating injury is evolving. The correct response is to pause the correction, offer oral free water, and administer D5W intravenously if oral intake is inadequate, targeting a final 24-hour rise no greater than 10 to 12 mEq/L from the starting point.

Option A: Option A is incorrect: a safe ceiling of 20 mEq/L per 24 hours does not exist in any established guideline for chronic hyponatremia; the absolute ceiling is 10 to 12 mEq/L per 24 hours, and this patient is on track to exceed it significantly.
Option C: Option C is incorrect: the safe correction rate applies to the rate of change from the starting sodium, not to the absolute sodium level reached; ODS risk is determined by the magnitude and speed of the osmolality shift relative to what brain cells have adapted to, not by whether the final sodium crosses 135 mEq/L.
Option D: Option D is incorrect: the 10 to 12 mEq/L per 24 hours ceiling applies to all patients with chronic hyponatremia regardless of the starting sodium; ODS risk may be particularly high at very low starting sodiums (where brain adaptation is more extensive), making the correction ceiling arguably more critical rather than less applicable at 116 mEq/L.
Option E: Option E is incorrect: a rise of 13 mEq/L in 14 hours of active treatment reflects the effect of the treating agent, not spontaneous SIADH resolution; the SIADH physiology (elevated urine osmolality, urine sodium above 40 mEq/L, euvolemia) remains present, and discontinuing treatment without addressing the rate of rise would leave the overcorrection unchecked rather than corrected.